RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on October 1, 2019, by Relmada Therapeutics, Inc., a Nevada corporation. The report details capital raising activities and a reverse stock split that occurred in September 2019.
Key Financial Metrics and Capital Events
The filing discloses three distinct capital events in September 2019, with share counts and prices adjusted for a 1-for-4 reverse stock split effective September 30, 2019:
- Warrant Exercise: 75,000 warrants exercised at $6.00 per share, generating net proceeds of $450,000.
- Private Placement (Sept 23): Issuance of 75,108 shares at $7.00 per share, generating net proceeds of $525,750.
- Private Placement (Sept 26): Issuance of 42,857 shares at $7.00 per share, generating net proceeds of $300,000.
Total Net Proceeds: $1,275,750 from the combined events.
The filing includes a pro forma balance sheet as of June 30, 2019, reflecting these proceeds. Specific revenue, profit, cash flow, or debt figures for the period are not provided in this text; the filing focuses solely on the equity transactions.
Material Changes
The primary material change is the increase in cash liquidity and outstanding share count resulting from the warrant exercises and private placements. Additionally, the company executed a 1-for-4 reverse stock split, which adjusted the share counts and prices reported in this filing.
Outlook, Risks, and Management Commentary
Management commentary is limited to the disclosure of the completed transactions and the attachment of a pro forma balance sheet. No specific forward-looking guidance, risk factors, or contingencies are detailed in the text of this specific 8-K filing.
Key Facts for Investor Verification
- Verify the total cash impact of $1,275,750 on the company's liquidity position.
- Confirm the adjusted share count post-1-for-4 reverse split.
- Review the attached Exhibit 99.1 (Pro Forma Balance Sheet) for the updated financial position as of June 30, 2019.
- Note that the filing does not provide operational metrics or revenue data for the period.